Immunocore Holdings plc Deferred Income Tax Expense (Benefit)
Immunocore Holdings plc (IMCR) reported Deferred Income Tax Expense (Benefit) of $14.79 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-25
- Immunocore Holdings plc deferred income tax expense (benefit) for fiscal 2025 was $14.79M.
- Immunocore Holdings plc deferred income tax expense (benefit) for fiscal 2024 was -$3.82M.
- Immunocore Holdings plc deferred income tax expense (benefit) for fiscal 2023 was -$5.84M.
- Immunocore Holdings plc deferred income tax expense (benefit) for fiscal 2022 was -$1.73M, a 1958.06% decline from fiscal 2021.
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $14.79M 10-K · filed 2026-02-25 | |
| 2024-12-31 | -$3.82M 10-K · filed 2026-02-25 | |
| 2023-12-31 | -$5.84M 10-K · filed 2026-02-25 | $5.84M 10-K · filed 2024-02-28 |
| 2022-12-31 | -$1.73M 10-K · filed 2025-02-26 | $1.73M 10-K · filed 2024-02-28 |
| 2021-12-31 | $93.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |